Tim Lugo
Stock Analyst at William Blair
(0.20)
# 3,261
Out of 4,413 analysts
23
Total ratings
18.75%
Success rate
-20.43%
Average return
Main Sectors:
Top Industries:
17 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LENZ LENZ Therapeutics | Initiates: Outperform | n/a | $15.81 | - | 1 | Apr 15, 2024 | |
| SLDB Solid Biosciences | Initiates: Outperform | $40 | $9.54 | +319.29% | 1 | Mar 28, 2024 | |
| ZVRA Zevra Therapeutics | Initiates: Outperform | n/a | $4.60 | - | 1 | Mar 12, 2024 | |
| ABBV AbbVie | Upgrades: Outperform | n/a | $161.72 | - | 2 | Jan 29, 2024 | |
| ALLK Allakos | Upgrades: Outperform | n/a | $1.13 | - | 2 | Dec 18, 2023 | |
| ACRS Aclaris Therapeutics | Downgrades: Market Perform | n/a | $1.26 | - | 1 | Nov 13, 2023 | |
| EYEN Eyenovia | Initiates: Outperform | n/a | $0.92 | - | 1 | Nov 1, 2023 | |
| TVTX Travere Therapeutics | Downgrades: Market Perform | n/a | $6.00 | - | 1 | Sep 21, 2023 | |
| SPRY ARS Pharmaceuticals | Downgrades: Market Perform | n/a | $9.33 | - | 2 | Sep 20, 2023 | |
| VTGN VistaGen Therapeutics | Downgrades: Market Perform | n/a | $4.74 | - | 2 | Jul 22, 2022 | |
| BMRN BioMarin Pharmaceutical | Upgrades: Outperform | n/a | $83.33 | - | 2 | Nov 22, 2021 | |
| SAGE Sage Therapeutics | Downgrades: Market Perform | n/a | $13.28 | - | 1 | Jun 16, 2021 | |
| AVIR Atea Pharmaceuticals | Initiates: Outperform | n/a | $3.85 | - | 1 | Nov 24, 2020 | |
| XENE Xenon Pharmaceuticals | Initiates: Outperform | n/a | $42.49 | - | 1 | Jan 8, 2020 | |
| AKTX Akari Therapeutics, | Upgrades: Outperform | n/a | $1.70 | - | 2 | Sep 22, 2017 | |
| OVID Ovid Therapeutics | Initiates: Outperform | n/a | $3.06 | - | 1 | May 30, 2017 | |
| BHVN Biohaven Pharmaceutical Holding Company | Initiates: Outperform | n/a | $40.18 | - | 1 | May 30, 2017 |
LENZ Therapeutics
Apr 15, 2024
Initiates: Outperform
Price Target: n/a
Current: $15.81
Upside: -
Solid Biosciences
Mar 28, 2024
Initiates: Outperform
Price Target: $40
Current: $9.54
Upside: +319.29%
Zevra Therapeutics
Mar 12, 2024
Initiates: Outperform
Price Target: n/a
Current: $4.60
Upside: -
AbbVie
Jan 29, 2024
Upgrades: Outperform
Price Target: n/a
Current: $161.72
Upside: -
Allakos
Dec 18, 2023
Upgrades: Outperform
Price Target: n/a
Current: $1.13
Upside: -
Aclaris Therapeutics
Nov 13, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.26
Upside: -
Eyenovia
Nov 1, 2023
Initiates: Outperform
Price Target: n/a
Current: $0.92
Upside: -
Travere Therapeutics
Sep 21, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $6.00
Upside: -
ARS Pharmaceuticals
Sep 20, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $9.33
Upside: -
VistaGen Therapeutics
Jul 22, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $4.74
Upside: -
BioMarin Pharmaceutical
Nov 22, 2021
Upgrades: Outperform
Price Target: n/a
Current: $83.33
Upside: -
Sage Therapeutics
Jun 16, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $13.28
Upside: -
Atea Pharmaceuticals
Nov 24, 2020
Initiates: Outperform
Price Target: n/a
Current: $3.85
Upside: -
Xenon Pharmaceuticals
Jan 8, 2020
Initiates: Outperform
Price Target: n/a
Current: $42.49
Upside: -
Akari Therapeutics,
Sep 22, 2017
Upgrades: Outperform
Price Target: n/a
Current: $1.70
Upside: -
Ovid Therapeutics
May 30, 2017
Initiates: Outperform
Price Target: n/a
Current: $3.06
Upside: -
Biohaven Pharmaceutical Holding Company
May 30, 2017
Initiates: Outperform
Price Target: n/a
Current: $40.18
Upside: -